Apollomics (APLM) Receivables (2025)
Apollomics (APLM) posted quarterly Receivables of $2.3 million for Q4 2025.
Apollomics (APLM) Receivables (2025) Analysis & Trends
Apollomics (APLM) has reported Receivables for 1 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables changed N/A year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (changed N/A YoY), while the FY2025 annual figure was $2.3 million, changed N/A from the prior year.
- Receivables was little changed at $2.3 million in Q4 2025 per APLM's latest filing.
- Across five years, Receivables topped out at $2.3 million in Q4 2025 and bottomed at $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Apollomics | 33.16 Mn | 29.88 Mn | - | 2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.31 Mn |